Healthcare Industry News: cervical cancer
News Release - June 19, 2007
Beckman Coulter, Inc. Dismissed in Case Against Ventana Medical Systems, Inc.GAITHERSBURG, Md., June 19 (HSMN NewsFeed) -- Digene Corporation (Nasdaq: DIGE ) announced today that on June 12, 2007, the United States District Court for the District of Delaware granted Beckman's motion to be dismissed from Digene's ongoing patent infringement action against Ventana Medical Systems, Inc. and Beckman Coulter, Inc.
Daryl Faulkner, president and chief executive officer of Digene, stated: "The claims between Digene and Beckman were decided in the initial arbitration, which was held in March 2006. Digene is pleased with the outcome of that arbitration, in which the arbitration panel upheld important contractual rights of Digene's relating to HPV materials and intellectual property, and found that Beckman's sales of certain HPV materials to Ventana and attempted assignment of HPV patent rights to Ventana was impermissible. With this motion behind us, we expect to continue our efforts to defend our intellectual property rights."
The patent infringement litigation against Ventana is continuing, and trial has been set to begin on December 17, 2007. Refer to the corporation's filings with the Securities and Exchange Commission for more information about its claims against Ventana. Digene will continue to vigorously pursue this litigation.
A leader in molecular diagnostics, Digene develops, manufactures and markets proprietary DNA and RNA tests, with a focus on women's health. The company's flagship product, the Digene® HPV Test, is the only FDA-approved and CE-marked test for the detection of human papillomavirus, the cause of essentially all cervical cancers. Digene's product portfolio also includes tests for the detection of other sexually transmitted infections, including chlamydia and gonorrhea. Digene tests are marketed in more than 40 countries worldwide. Headquartered in Gaithersburg, MD, Digene is traded on NASDAQ under the symbol DIGE. For more information, visit http://www.digene.com and http://www.theHPVtest.com.
Digene®, Hybrid Capture®, hc2 High-Risk HPV DNA Test® and DNAwithPap® are registered trademarks of Digene Corporation.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of the future as there are a number of meaningful factors that could cause the Company's actual results to vary materially from those indicated by such forward-looking statements. Meaningful factors, which could cause actual results to differ from expectations include, but are not limited to, risk that other companies may develop and market HPV tests competitive with our own; our ability to scale up our manufacturing to the extent demand for our products increases; ability to develop new products; ability to execute and integrate strategic transactions; uncertainty related to changes in our senior management; and uncertainty of market acceptance of our products by the worldwide medical community, as well as other factors discussed in the Company's Securities and Exchange Commission filings. For other factors, reference is made to the Company's annual and quarterly reports filed with the Securities and Exchange Commission.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.